Vaxcyte Raises $2.7B Cash, Completes Enrollment in Three Phase 3 VAX-31 Trials
PCVX•Vaxcyte completed enrollment of 6,191 adults in Phase 3 OPUS trials evaluating its VAX-31 pneumococcal conjugate vaccine, with topline safety and immunogenicity data due Q4 2026 for OPUS-1 and H1 2027 for OPUS-2 and OPUS-3. It holds $2.7 billion in cash and expects to initiate a Phase 1 VAX-A1 study mid-2026.
1. Enrollment Completed in Phase 3 OPUS Trials
Vaxcyte has now fully enrolled three OPUS Phase 3 clinical trials for its VAX-31 pneumococcal conjugate vaccine, dosing 6,191 adults across OPUS-1 noninferiority comparisons with PCV20 and PCV21, OPUS-2 influenza co-administration, and OPUS-3 booster evaluation in previously vaccinated cohorts.
2. Upcoming Data Readouts and Regulatory Path
The company expects topline safety, tolerability and immunogenicity data from OPUS-1 in Q4 2026, followed by OPUS-2 and OPUS-3 results in H1 2027. These readouts are designed to support the planned Biologics License Application submission and potential U.S. commercial launch, leveraging a carrier-sparing platform that could expand invasive pneumococcal disease coverage by 14–34%.
3. Cash Position and VAX-A1 Phase 1 Launch
As of March 31, 2026, Vaxcyte held $2.7 billion in cash, cash equivalents and investments, including $601.8 million from a February equity offering. This strong balance sheet underpins the planned mid-2026 initiation of a Phase 1 adult study for VAX-A1, a prophylactic vaccine candidate targeting Group A Streptococcus disease prevention.
